GCP
SKYE icon

GSA Capital Partners’s Skye Bioscience SKYE Stock Holding History

GSA Capital Partners’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,877
Closed -$17K – 2233
2025
Q4 		$17K Buy
+22,877
New +$33.4K ﹤0.01% 1603

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

GSA Capital Partners's SKYE Position: Q1 2026 in Review

GSA Capital Partners sold out of Skye Bioscience (SKYE) in Q1 2026, closing a stake of 22,877 shares — an estimated $17K sold.

GSA Capital Partners first reported a position in SKYE in Q4 2025 and held it in 1 quarter. The position peaked at $17K in Q4 2025. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • GSA Capital Partners reported no remaining Skye Bioscience position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 22,877 Skye Bioscience shares in Q1 2026, an estimated $17K.
  • GSA Capital Partners first reported a position in Skye Bioscience in Q4 2025 and held it in 1 quarter.
  • GSA Capital Partners's Skye Bioscience position peaked at $17K in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.